Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. - Wikidata - wikimedia - TriplyDB

Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors.

Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors.

http://www.wikidata.org/entity/Q41318528

about

Cardiovascular gene therapy for myocardial infarction Gene therapy for hemophilia Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.The potential of adeno-associated viral vectors for gene delivery to muscle tissue.Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo.Strategies to circumvent humoral immunity to adeno-associated viral vectors.Adeno-associated viral vectors for the treatment of hemophilia.Immune responses to AAV vectors: overcoming barriers to successful gene therapy Humoral Immune Response to AAV.Gene therapy to treat cardiovascular disease.Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors.Current status of haemophilia gene therapy.Obstacles and future of gene therapy for hemophilia.New approaches to gene and cell therapy for hemophilia.Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity.Unraveling the complex story of immune responses to AAV vectors trial after trial.Flushing out antibodies to make AAV gene therapy available to more patients.Overcoming preexisting humoral immunity to AAV using capsid decoys The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals.Covert warfare against the immune system: decoy capsids, stealth genomes, and suppressors.Emerging Issues in AAV-Mediated In Vivo Gene Therapy.Gene therapy for hemophilia: what does the future hold?

P2860

Q27014770-3D94E6C4-E800-498A-AB47-DC1CAF43666B Q28081911-EBF89A14-36A3-4251-98A6-5AAC9CFAF264 Q30152887-68E05569-B9A4-4DDB-B31B-53D2C23E2BA2 Q33830117-DAA5E69C-3E86-42F2-99B0-EB454CFA19D8 Q33902499-889C06D0-36D4-423D-8B20-32F6685214B1 Q33924645-2A9D947A-3138-4ED0-B8B9-C6CA2B41778A Q36398678-7789844C-00B8-4AE6-9855-AB98B15F767B Q36713767-470B28A9-9910-4E58-BA1B-19D02D0F532C Q36983740-0234721A-01FB-4646-823B-D476AF1DEB76 Q37236099-7F5D3760-2D58-4A51-AE09-5D5380609A38 Q37310450-D4FF3442-418C-4A04-BCCB-2F680D51FC53 Q38191212-91FC7937-55AD-410E-BEDE-056B5D863A3C Q38206852-F62F851D-B54A-49C0-A261-C42B537449E9 Q38529941-1CF8DAF0-5FBE-4E2E-AB23-0459C1A34752 Q38543280-6ED3B098-8E9B-413F-BAD2-2C47D79A2AC5 Q38684383-2968BBD4-8FDF-4A08-BD28-932D90CD26A2 Q40073271-727B34F5-4415-436D-AC1C-6B28BA0DDFD7 Q41171011-3CE518A4-3E1A-4D78-BB15-4EF70A1BF943 Q42056009-7EBB2654-BDE2-40A0-B234-2C5C7A4B3B6F Q42261520-108019BC-F260-43EF-96C6-9AD360B538F3 Q42271911-CFE4CBB9-2291-4E06-A6C2-578E214E0608 Q47554736-388640D2-8C74-4968-89CD-ED8B39AD3D69 Q57167448-EAF105CD-B4CF-4DCB-88EA-C742EFA0A20F

P2860

Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors.

http://www.wikidata.org/entity/Q41318528

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Minimizing the inhibitory effe ...... no-associated virus 8 vectors.

@en

type

label

Minimizing the inhibitory effe ...... no-associated virus 8 vectors.

@en

prefLabel

Minimizing the inhibitory effe ...... no-associated virus 8 vectors.

@en

P1433

Q41318528-85803080-376A-46BD-8BBF-7B5CF33165D6

P1476

Q41318528-D811B73D-897A-4CC9-8FD3-73B19C5352D5

P2093

Q41318528-1758A422-BA4A-4FA3-8F89-C6F2D5A18253

Q41318528-2F755086-0BDB-4507-9A22-C8EBDE06D37E

Q41318528-37C68BF6-7C10-44B2-8CDA-4AA084D64F75

Q41318528-60FCC18E-4313-42E5-B207-437114280AF1

Q41318528-8179F73F-D629-4586-BC4C-B70E7EF9E044

Q41318528-9D145DF1-48FC-4809-8488-97A6173AEE5B

Q41318528-C12B0CB4-E699-417B-BABE-C6B1ED6576A3

Q41318528-D7ECB580-BD05-408B-9B51-41D67F1F87D9

Q41318528-ED72684B-4D66-4C50-8CE4-65B6E87527D1

Q41318528-FA9962A9-049E-4C1D-B78F-D08DA877990B

P2860

Q41318528-00EFA91F-AC62-4388-9016-BA5E6E387177

Q41318528-101F3DE9-726C-468F-89D1-906B1543136F

Q41318528-1A306FC2-7CD9-4D25-904B-BEE73CEF8858

Q41318528-1EB619F9-1128-43BD-BD37-577CAE89F9AB

Q41318528-2228E1BD-AF78-4DB4-825A-AADE3D7C2B09

Q41318528-22E0B40E-5B77-43A2-8858-AFFAAF8A3892

Q41318528-2B1315EA-F7D9-49C2-8668-E4A19FD21849

Q41318528-3039C879-C810-42A5-ADC6-6BB40C509B9E

Q41318528-33C28091-098F-4344-AFB6-90514F807C39

Q41318528-369E6D54-CA96-4900-A285-7578B4A882D0

P304

Q41318528-EEF4009D-8951-44F2-AE9F-6986428D58F0

P31

Q41318528-F7E58AF7-A4F3-44FB-930D-BA1D22501CF3

P356

Q41318528-0E483B70-19A0-4784-A19D-4B4EE79428CC

P433

Q41318528-8DA5D66C-83C5-460F-B5E8-9DA2046AB2F9

P478

Q41318528-18D76021-B2D6-4195-AE7F-8FE1183F8FBE

P50

Q41318528-575117F1-22D4-45AF-9859-2F3FA1A6D221

P577

Q41318528-AEBE024D-19B7-49D5-BBA4-6258C3D8D540

P5875

Q41318528-02AB0C19-FDDF-4A01-9DE2-2EB9EF221D70

P698

Q41318528-E7510BF1-DFA3-4DB0-939B-ED998E4FF0DF

P921

Q41318528-78DB5736-F9C4-427C-BDE0-DC787D57B340

P932

Q41318528-6A0C0C89-1297-4110-8D5A-CF32BB3A60C1

P356

P1433

Molecular Therapy

P1476

Minimizing the inhibitory effe ...... eno-associated virus 8 vectors

@en

P2093

Akira Ishiwata

http://www.w3.org/2001/XMLSchema#string

Asuka Sakata

http://www.w3.org/2001/XMLSchema#string

Fumiko Ono

http://www.w3.org/2001/XMLSchema#string

Hiroaki Mizukami

http://www.w3.org/2001/XMLSchema#string

Jun Mimuro

http://www.w3.org/2001/XMLSchema#string

Keiya Ozawa

http://www.w3.org/2001/XMLSchema#string

Seiji Madoiwa

http://www.w3.org/2001/XMLSchema#string

Shuji Hishikawa

http://www.w3.org/2001/XMLSchema#string

Tomokazu Ikemoto

http://www.w3.org/2001/XMLSchema#string

Yoichi Sakata

http://www.w3.org/2001/XMLSchema#string

P2860

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

AAV-mediated liver-directed gene therapy.

Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.

AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

The hemophilias--from royal genes to gene therapy.

Expression of the adenovirus E4 34k oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell line.

Gene therapy for haemophilia.

Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.

A barrel of monkeys: scAAV8 gene therapy for hemophilia in nonhuman primates.

P304

318-323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2012.258

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233940848

http://www.w3.org/2001/XMLSchema#string

P698

23247100

http://www.w3.org/2001/XMLSchema#string

P921

vector-borne disease

P932

3594013

http://www.w3.org/2001/XMLSchema#string